First patients test new cancer drug in early safety trial
NCT ID NCT06546553
Summary
This was an early-stage study to test the safety and find the right dose of a new cancer drug called PF-07826390. It was given alone or combined with another immunotherapy drug to people with advanced solid tumors that had spread or stopped responding to treatment. The main goal was to see how well the body tolerated the medicine and to check for side effects.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes NO responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for RENAL CELL CARCINOMA are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Locations
-
Beverly Hills Cancer Center
Beverly Hills, California, 90211, United States
-
Florida Cancer Specialists
Orlando, Florida, 32827, United States
-
Florida Cancer Specialists & Research Institute, LLC
Fort Myers, Florida, 33916, United States
-
START Midwest
Grand Rapids, Michigan, 49546, United States
-
START Mountain Region
West Valley City, Utah, 84119, United States
-
START San Antonio
San Antonio, Texas, 78229, United States
-
Sarah Cannon Research Institute at Florida Cancer Specialists
Orlando, Florida, 32827, United States
-
Virginia Cancer Specialists
Fairfax, Virginia, 22031, United States
Conditions
Explore the condition pages connected to this study.